News Ouro makes debut with $120m for autoimmune disease TCEs Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.
News Verdiva Bio raises $411m for obesity pipeline A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.
News Aviceda raises $207.5m for eye drug, and other financings Our round-up of recent biotech financings includes a big round for Aviceda, with Orbis, Alebund, XyloCor, and PrimeGene also raising additional cash.
News NeOnc Technologies has another go at a Nasdaq listing US biotech NeOnc Technologies has applied to list on the Nasdaq as it advances a portfolio of drugs to treat diseases affecting the CNS.
News Neuralink rival Precision raises $102m, and other financings Neuralink rival Precision Neurosciences raises $102m for its brain-computer interface tech, plus financings for Redesign, DeepLife, TG0 and Tuva.
News Ottimo raises $140m for its PD-1/VEGF cancer drug Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.
R&D CDMOs: Their crucial role and how to select one, with Sigma ... Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.